Michael L O'Byrne1,2, Andrew C Glatz1,2, Joseph W Rossano1, Kellie L Schiavo1, Yoav Dori1, Jonathan J Rome1, Matthew J Gillespie1. 1. Division of Cardiology, The Children's Hospital of Philadelphia and Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania, Pennsylvania. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Pennsylvania.
Abstract
OBJECTIVE: To describe our center's middle-term outcomes following trans-catheter creation of atrial communication (ASD) in patients on mechanical circulatory support. BACKGROUND: Trans-catheter creation of an ASD in patients on mechanical circulatory support is an adjuvant therapy to reduce left atrial pressure and associated morbidity. Data on middle term outcomes following this procedure, specifically in regards to the fate of the ASD, are limited. METHODS: Retrospective observational study of consecutive children and adults undergoing trans-catheter creation of an atrial septal communication between 1/1/2006 and 5/1/2014, reviewing their baseline characteristics, procedural details, and data from follow-up. RESULTS: Over the study period, 37/227 (16%) subjects undergoing veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) underwent trans-catheter creation of an atrial communication. Mortality on VA-ECMO support in this subgroup was 19%, with an additional 24% transitioning to ventricular assist device. Of the 57% who survived to separation from VA-ECMO, 16/21 (76%) had residual atrial communications. 56% of these underwent closure procedures. CONCLUSIONS: Following trans-catheter creation of ASD, a residual ASD is present in the majority of assessable survivors and represents a potential volume overload and/or right to left shunt that may need to be addressed.
OBJECTIVE: To describe our center's middle-term outcomes following trans-catheter creation of atrial communication (ASD) in patients on mechanical circulatory support. BACKGROUND: Trans-catheter creation of an ASD in patients on mechanical circulatory support is an adjuvant therapy to reduce left atrial pressure and associated morbidity. Data on middle term outcomes following this procedure, specifically in regards to the fate of the ASD, are limited. METHODS: Retrospective observational study of consecutive children and adults undergoing trans-catheter creation of an atrial septal communication between 1/1/2006 and 5/1/2014, reviewing their baseline characteristics, procedural details, and data from follow-up. RESULTS: Over the study period, 37/227 (16%) subjects undergoing veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) underwent trans-catheter creation of an atrial communication. Mortality on VA-ECMO support in this subgroup was 19%, with an additional 24% transitioning to ventricular assist device. Of the 57% who survived to separation from VA-ECMO, 16/21 (76%) had residual atrial communications. 56% of these underwent closure procedures. CONCLUSIONS: Following trans-catheter creation of ASD, a residual ASD is present in the majority of assessable survivors and represents a potential volume overload and/or right to left shunt that may need to be addressed.
Authors: G R Veldtman; G Norgard; H Wåhlander; Y Garty; O Thabit; B W McCrindle; K J Lee; L N Benson Journal: Pediatr Cardiol Date: 2005 Mar-Apr Impact factor: 1.655
Authors: David L S Morales; Farhan Zafar; Joseph W Rossano; Jorge D Salazar; John L Jefferies; Daniel E Graves; Jeffrey S Heinle; Charles D Fraser Journal: Ann Thorac Surg Date: 2010-10 Impact factor: 4.330
Authors: P M Seib; S C Faulkner; C C Erickson; S H Van Devanter; J E Harrell; J W Fasules; E A Frazier; W R Morrow Journal: Catheter Cardiovasc Interv Date: 1999-02 Impact factor: 2.692
Authors: Enzo Lüsebrink; Leonhard Binzenhöfer; Antonia Kellnar; Christoph Müller; Clemens Scherer; Benedikt Schrage; Dominik Joskowiak; Tobias Petzold; Daniel Braun; Stefan Brunner; Sven Peterss; Jörg Hausleiter; Sebastian Zimmer; Frank Born; Dirk Westermann; Holger Thiele; Andreas Schäfer; Christian Hagl; Steffen Massberg; Martin Orban Journal: Clin Res Cardiol Date: 2022-08-20 Impact factor: 6.138